University of Maryland, Baltimore Patent applications |
Patent application number | Title | Published |
20160139012 | METHODS AND DEVICES FOR HIGH THROUGHPUT PURIFICATION - Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes. | 05-19-2016 |
20160129109 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 05-12-2016 |
20160081652 | COAPTATION ULTRASOUND DEVICES AND METHODS OF USE - Disclosed is a system and method for the placement of elongate medical members within a patient's body using coaptive ultrasound that combines magnetic guidance with ultrasound visualization of the medical member in the patient's body. A coaptive ultrasound probe adaptor magnetically attracts an elongate medical member within the patient with sufficient force so as to allow the operator to manually guide the member to its intended location. The adaptor mates with an ultrasound probe to provide the medical operator ultrasound feedback of the position of the member, thus allowing internal placement without the need for more specialized medical equipment. | 03-24-2016 |
20160070850 | METHOD FOR BINDING SITE IDENTIFICATION BY MOLECULAR DYNAMICS SIMULATION (SILCS: SITE IDENTIFICATION BY LIGAND COMPETITIVE SATURATION) - The invention describes an explicit solvent all-atom molecular dynamics methodology (SILCS: Site Identification by Ligand Competitive Saturation) that uses no small aliphatic and aromatic molecules plus water molecules to map the affinity pattern of a large molecule for hydrophobic groups, aromatic groups, hydrogen bond donors, and hydrogen bond acceptors. By simultaneously incorporating ligands representative of all these functionalities, the method is an in silico free energy-based competition assay that generates three-dimensional probability maps of fragment binding (FragMaps) indicating favorable fragment:large molecule interactions. The FragMaps may be used to qualitatively inform the design of small-molecule ligands or as scoring grids for high-throughput in silico docking that incorporates both an atomic-level description of solvation and the large molecule's flexibility. | 03-10-2016 |
20160047761 | ASSESSING BIOPHARMACEUTICAL AGGREGATION USING MAGNETIC RESONANCE RELAXOMETRY - The present invention generally relates to a method of using NMR relaxation rates (R | 02-18-2016 |
20160038476 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY - Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy. | 02-11-2016 |
20160022717 | ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS - The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) | 01-28-2016 |
20160000859 | PEPTIDE ADDITIVES FOR ENHANCING ACCEPTANCE AND INGESTION OF EDIBLES BY RODENTS AND USES THEREOF - Methods of using of guanylin family peptides to induce food or odor preferences in mammals are provided, along with methods for inducing feeding responses in mammals, and methods of controlling pest populations of mammals, such as rodents. | 01-07-2016 |
20150335709 | Colostrum Composition Enriched in Anti-Endotoxin Antibodies - The present invention provides a colostrum formulation enriched in broadly cross-reactive anti-endotoxin antibodies. Further provided is a method for reducing endotoxemia and blocking the onset of sepsis in patients comprising administering to the patients a colostrum formulation enriched with anti-endotoxin antibodies. Further provided is a method for treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome, comprising the step of administering to the patient an effective amount of the composition of the present invention. | 11-26-2015 |
20150299345 | ANTIBACTERIAL MONOMERS, ANTIBACTERIAL RESINS AND DENTAL COMPOSITES COMPRISING THE ANTIBACTERIAL RESINS - Provided herein are antibacterial monomers, antibacterial resins comprising a resin and the monomers, and dental composites comprising the antibacterial resins and a filler, and methods of making the same. The dental composite can optionally contain amorphous calcium phosphate nanoparticles. The dental composites display strongly antibacterial properties, increased calcium and phosphate ion release, and improved mechanical properties. | 10-22-2015 |
20150299268 | HIV-1 ENV-BINDING ANTIBODIES, FUSION PROTEINS, AND METHODS OF USE - Fusion proteins comprising a portion of the HIV-1 Env protein and ScFv of an enhancing antibody are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection. A broadly neutralizing antibody and engineered bi-/tri-specific anti-HIV-1 antibodies that may serve in the prevention and/or treatment of HIV-1 infections in a subject are also disclosed, as well as methods of using the fusions proteins and antibodies. | 10-22-2015 |
20150259438 | METHODS OF INHIBITING PLATELET AGGREGATION AND PREVENTING THROMBOSIS USING ANTIBODIES THAT BIND (NA+ + K+)-ATPASE BETA SUBUNIT - Methods of inhibiting platelet aggregation using antibodies having binding specificity for the β subunit of the (Na | 09-17-2015 |
20150231176 | Compositions and Methods for the Treatment of Cancers - The present invention provides a formulation comprising dichloroacetate and arsenic trioxide. The present invention also provides a method of treating cancer by administering a therapeutically effective amount of dichloroacetate and arsenic trioxide. | 08-20-2015 |
20150218519 | STEM CELL CULTURE MEDIUM AND METHOD OF USING SAID MEDIUM AND THE CELLS - The present invention relates to methods and compositions concerning isolation of proliferating cells. In particular, the invention regards enrichment of stem cells in a mixture of stem cells and non-stem cells, wherein the non-stem cells may be differentiated cells. The invention exploits the non-adherent property of stem cells, as opposed to the adherent property of differentiating cells, by serially passaging the suspended cells in liquid media. | 08-06-2015 |
20150216959 | BACTERIAL LIVE VECTOR VACCINES EXPRESSING CHROMOSOMALLY-INTEGRATED FOREIGN ANTIGENS - Bacterial live vector vaccines represent a vaccine development strategy that offers exceptional flexibility. In the present invention, genes encoding protective antigens of unrelated bacterial, viral, parasitic, or fungal pathogens are expressed in an attenuated bacterial vaccine strain that delivers these foreign antigens to the immune system, thereby eliciting relevant immune responses. Rather than expressing these antigens using only low copy expression plasmids, expression of foreign proteins is accomplished using both low copy expression plasmids in conjunction with chromosomal integrations within the same live vector. This strategy compensates for the inherent disadvantage of loss of gene dosage (versus exclusive plasmid-based expression) by integrating antigen expression cassettes into multiple chromosomal sites already inactivated in an attenuated vector. | 08-06-2015 |
20150211037 | POLYPEPTIDES FOR USE IN THE DECONSTRUCTION OF CELLULOSE - Hydrolysis and degradation of cellulose-containing biomass by use of a polypeptide having cellulase activity is provided. Also provided are polypeptides having cellulase activity, such as archaeal cellulases, polynucleotides encoding the polypeptides, and compositions containing the polypeptides, and methods of use thereof. | 07-30-2015 |
20150174228 | Detoxified Endotoxin Immunogenic Compositions and Uses Thereof - The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of | 06-25-2015 |
20150064153 | HIGH EFFICIENCY MICROFLUIDIC PURIFICATION OF STEM CELLS TO IMPROVE TRANSPLANTS - Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes. | 03-05-2015 |
20150056185 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 02-26-2015 |
20150032127 | TRANSAPICAL MITRAL VALVE REPAIR METHOD - Methods and devices for repairing a cardiac valve. A minimally invasive procedure includes creating an access in the apex region of the heart through which one or more instruments may be inserted. The device can implant artificial heart valve chordae tendineae into cardiac valve leaflet tissues to restore proper leaflet function and prevent reperfusion. The device punctures the apex of the heart and travels through the ventricle. The tip of the device rests on the defective valve and punctures the valve leaflet. A suture or a suture/guide wire combination is inserted, securing the top of the leaflet to the apex of the heart. A resilient element or shock absorber mechanism adjacent to the outside of the apex of the heart minimizes the linear travel of the device in response to the beating of the heart or opening/closing of the valve. | 01-29-2015 |
20150030664 | BLOOD COAGULATION INDUCING POLYMER HYDROGEL - The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated. | 01-29-2015 |
20150024000 | MULTIVALENT VACCINE PROTECTION FROM STAPHYLOCOCCUS AUREUS INFECTION - Vaccine formulations effective against | 01-22-2015 |
20140363818 | EGFR and PAR2 Regulation of Intestinal Permeability - The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR | 12-11-2014 |
20140356415 | COMPOSITIONS AND VACCINES COMPRISING VESICLES AND METHODS OF USING THE SAME - The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer. | 12-04-2014 |
20140296307 | POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY - The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1′-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5). | 10-02-2014 |
20140288022 | CROSS-LINKED POLYMER MATRICES, AND METHODS OF MAKING AND USING SAME - Functionalized chondroitin sulfate, cross-linked polymer matrices comprising functionalized chondroitin sulfate, and methods of making and using the same are provided. Such polymer matrices may be used for tissue engineering, reconstructing cartilage, and the like. Kits are also provided for detection of cartilage degrading enzymes. | 09-25-2014 |
20140286932 | Giant Obscurins and Uses Thereof in Cancer Prognosis and Therapy - Provided herein are methods and kits for evaluating potential for invasiveness, metastasis, or recurrence of an epithelial cell cancer. In the methods the expression profile of giant obscurins is detected in a tissue sample of tumor cells or suspected tumor cells and assessed for giant obscuring expression level and distribution therein. Decreased levels or altered distribution of giant obscurins in the cells compared to a control non-invasive standard or to a sample taken at a different point in time is indicative of increased potential of at least one of the invasiveness, metastasis, or recurrence of the epithelial cell cancer. The kit comprises a detection reagent suitable for detecting the presence and distribution of giant obscurins or an amount of the gene product(s) encoding giant obscurins in cells of a tissue sample and instructions for using the detection reagent. | 09-25-2014 |
20140274983 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY - Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable pro-drug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia. | 09-18-2014 |
20140256817 | AMPHIPATHIC AND OTHER DOUBLE-SIDED ALPHA-HELIX MIMETICS BASED ON A 1,2-DIPHENYLACETYLENE SCAFFOLD - Small-molecule scaffolds based on 1,2-diphenylacetylene that accurately replicate the spatial and angular projections of several side chains on both faces of an α-helix, specifically the i and i+7 side chains on one face, and the i and i+2 side chains on the other. The amphipathic α-helix mimetic can be used to disrupt disease-promoting protein-protein interactions that are mediated by α-helices. | 09-11-2014 |
20140256593 | PLASMONIC SUBSTRATES FOR METAL-ENHANCED FLUORESCENCE BASED SENSING, IMAGING AND ASSAYS - Techniques for metal enhanced fluorescence include determining a calibration curve that relates concentration of a particular analyte to at least one of intensity or lifetime of fluorescent emissions at a functionalized substrate in response to incident light, for a plurality of known concentrations of the particular analyte mixed with a reagent. The functionalized substrate comprises a plasmonic substrate and a bioactive target molecule that has an affinity for the particular analyte. The reagent comprises a detection molecule. A concentration of the particular analyte in a sample is determined directly from the calibration curve and measurements, in response to the incident light, of at least one of intensity or lifetime of fluorescent emissions at the functionalized substrate in contact with the sample and reagent. | 09-11-2014 |
20140255397 | METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER - Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist. | 09-11-2014 |
20140235564 | METHODS FOR TREATING NEURAL CELL SWELLING - A composition comprising a novel Ca | 08-21-2014 |
20140206565 | Esophageal Cancer Markers - The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer. | 07-24-2014 |
20140179743 | NON-ATP DEPENDENT INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) - A compound, having the formula A-1: | 06-26-2014 |
20140128328 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the | 05-08-2014 |
20140128321 | METHOD AND USE OF PEPTIDE ANTAGONISTS OF ZONULIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 05-08-2014 |
20140114404 | TRANSAPICAL MITRAL VALVE REPAIR DEVICE - Methods and devices for repairing a cardiac valve. A minimally invasive procedure includes creating an access in the apex region of the heart through which one or more instruments may be inserted. The device can implant artificial heart valve chordae tendineae into cardiac valve leaflet tissues to restore proper leaflet function and prevent reperfusion. The device punctures the apex of the heart and travels through the ventricle. The tip of the device rests on the defective valve and punctures the valve leaflet. A suture or a suture/guide wire combination is inserted, securing the top of the leaflet to the apex of the heart. A resilient element or shock absorber mechanism adjacent to the outside of the apex of the heart minimizes the linear travel of the device in response to the beating of the heart or opening/closing of the valve. | 04-24-2014 |
20140105913 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 04-17-2014 |
20140046207 | Determination of site of origin for a natural electrical pulse in a living body - Techniques include determining a first vector of temporal changes in electrical data measured at multiple electrical sensors positioned at corresponding locations on a surface of a living body due to a natural electrical pulse. A different vector of temporal changes in electrical data measured at the same electrical sensors is determined due to each stimulated signal of multiple stimulated signals within the living body. Stimulated position data is received, which indicates a different corresponding position within the living body where each of the stimulated signals originates. The site of origin of the natural electrical pulse is determined based on the first vector and the multiple different vectors and the stimulated position data. Among other applications, these techniques allow the rapid, automatic determination of the site of origin of ventricular tachycardia arrhythmia (VT). | 02-13-2014 |
20140043618 | Coherence Gated Doppler Motion Sensor and Medical Applications - A motion sensor applicable to medical procedures includes a source of light with a wavelength bandwidth and an optical detector. A first optical coupler terminates in a first probe tip and couples the light into the first probe tip. A second optical coupler terminates in a second probe tip and directs onto the detector scattered light returning through the second probe tip. A presentation device outputs a signal that indicates motion in a target volume of a sample in a vicinity of the probe tips based on a Doppler shift of the scattered light. The volume depends on coherence distance determined by the bandwidth. In variations, the first and second tips are the same tip, a multimode fiber is included, the bandwidth is between 0.1% and 5% of a center wavelength, or the presentation device is a speaker, or some combination. | 02-13-2014 |
20130337003 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 12-19-2013 |
20130316971 | USE OF TREHALOSE FOR PREVENTION OF NEURAL TUBE DEFECTS - Maternal diabetes suppresses autophagy in neuroepithelial cells of the developing neural tube which leads to neural tube defect formation. Trehalose treatment reversed autophagy impairment and prevented neural tube defects in diabetic pregnancies. Trehalose resolved homeostatic imbalance by correcting mitochondrial defects, dysfunctional proteins, ER stress, apoptosis, and delayed neurogenesis in the neural tubes exposed to hyperglycemia. Methods of using trehalose as an intervention against hyperglycemia-induced neural tube defects are provided herein. | 11-28-2013 |
20130303899 | QUANTITATIVE EVALUATION OF FRACTIONAL REGIONAL VENTILATION USING FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY - Methods and systems for determining fractional regional ventilation are disclosed. A method includes obtaining first and second lung image data indicative of a first phase and a second phase of a respiratory cycle, respectively, determining an apparent mass ratio k based on the first lung image data and the second lung image data, determining first and second spatially matched lung image data, each including N voxels, based on the first lung image data and the second lung image data, and determining at least one fractional regional ventilation value (FRV value), in accordance with a first equation FRV(n)=(k·ρ2_n−ρ1_n)/ρ1_n. The value of n is a voxel index, ρ1_n is indicative of a density of a voxel n of the first spatially matched lung image data, and ρ2_n is indicative of a density of a voxel n of the second spatially matched lung image data. | 11-14-2013 |
20130296813 | SNAP-ON TWO-PIECE EMERGENCE PROFILE HEALING ABUTMENT - A snap-on two-piece emergence profile healing abutment provides a trans-gingival piece that can create various gingival shapes and contours of the dental implant emergence profile. The device consists of two main components: a central piece similar to standard healing abutments, having multiple facets; and an interchangeable outer piece used as a gingival emergence profile shell. The gingival emergence profile shell can be configured in various sizes and shapes to best estimate the size and shape of a dental crown to be restored. | 11-07-2013 |
20130295594 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CROHN'S DISEASE - The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated. | 11-07-2013 |
20130289081 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE - A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. | 10-31-2013 |
20130288950 | USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS - The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof. | 10-31-2013 |
20130287752 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 10-31-2013 |
20130231376 | DEFENSIN-LIKE MOLECULES AS NOVEL ANTIMICROBIAL AGENTS - Disclosed are methods of treating and/or preventing infections in mammals caused by microorganisms, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are the use of such defensin-like molecules for treating and/or preventing infections in mammals; and kits that may include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal. | 09-05-2013 |
20130218005 | MINIMALLY INVASIVE NEUROSURGICAL INTRACRANIAL ROBOT SYSTEM AND METHOD - Minimally invasive neurosurgical intracranial robot system is introduced to the operative site by a neurosurgeon through a narrow surgical corridor. The robot is passed through a cannula and is attached to the cannula by a latching mechanism. The robot has several links interconnected via revolute joints which are tendon-driven by tendons routed through channels formed in the walls of the links. The robot is teleoperatively guided by the neurosurgeon based on real-time images of the intracranial operative site and tracking information of the robot position. The robot body is equipped with a tracking system, tissue liquefacting end-effector, at as well as irrigation and suction tubes. Actuators for the tendon-driven mechanism are positioned at a distance from the imaging system to minimize distortion to the images. The tendon-actuated navigation of the robot permits an independent control of the revolute joints in the robot body. | 08-22-2013 |
20130203649 | INHIBITORS OF TLR SIGNALING BY TARGETING TIR DOMAIN INTERFACES - TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling. | 08-08-2013 |
20130197271 | DENDRIMERS AND METHODS OF PREPARING SAME THROUGH PROPORTIONATE BRANCHING - The present invention provides for monodispersed dendrimers having a core, branches and periphery ends, wherein the number of branches increases exponentially from the core to the periphery end and the length of the branches increases exponentially from the periphery end to the core, thereby providing for attachment of chemical species at the periphery ends without exhibiting steric hindrance. | 08-01-2013 |
20130190247 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 07-25-2013 |
20130177904 | ARNT ISOFORM 3 AS A PREDICTOR OF AMINOFLAVONE RESPONSIVENESS IN CANCER CELLS - The present invention is directed to methods for determining whether a selected cancer is susceptible to an activity of an arylhydrocarbon receptor agonist, such as aminoflavone, via screening the cancer for expression of isoform 3 of aryl hydrocarbon nuclear translocator. | 07-11-2013 |
20130157943 | METHOD AND USE OF PEPTIDE ANTAGONISTS OF ZONOLIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 06-20-2013 |
20130137857 | TRANSGLYCOSYLATION ACTIVITY OF GLYCOSYNTHASE MUTANTS OF AN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE (ENDO-D) FROM STREPTOCOCCUS PNEUMONIAE - The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain. | 05-30-2013 |
20130131108 | METHODS OF TREATING OBSTRUCTIVE LUNG DISEASES USING BITTER TASTANTS - Described herein are methods for enhancing airway dilation and/or relieving bronchoconstriction, e.g., to treat obstructive lung diseases such as asthma and COPD, by administering bitter tastants to subjects in need thereof. Also described herein are methods for identifying compounds that modulate function of bitter tastant receptors. | 05-23-2013 |
20130129776 | Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease - The present invention is drawn to multivalent | 05-23-2013 |
20130115637 | Efficiency of Prion Conversion in vitro and Sensitivity of Prion Detection - The present invention relates to improved methods and kits for the amplification detection of pathogenic prion proteins in samples. In some aspects of the invention, the method comprises: i) contacting the sample with a source of PrP | 05-09-2013 |
20130108708 | DENTAL COMPOSITES COMPRISING NANOPARTICLES OF AMORPHOUS CALCIUM PHOSPHATE | 05-02-2013 |
20130060251 | PROXIMAL HUMERUS GREATER TUBEROSITY HOOK-ARM CLIP - The invention relates to a bone plate for stabilizing a fractured greater tuberosity, wherein the bone plate comprises one or more apertures for fixing the bone plate to bone; one or more hook-arm receivers; one or more attachable hook-arms comprising one or more prongs and a device for attachment to the bone plate. The invention also relates to methods for stabilizing a fractured greater tuberosity using the bone plates of the invention and kits comprising the same. | 03-07-2013 |
20130057279 | Noninvasive Characterization of Mechanical Properties of Materials and Tissues Using Magnetic Resonance Techniques - Techniques include determining, non-invasively and without applying deformational stress, a nuclear magnetic resonance relaxation rate at a volume inside a subject. The method also includes determining a mechanical property of material at the volume inside the subject based on the nuclear magnetic resonance relaxation rate. | 03-07-2013 |
20130039990 | INJECTABLE, LOAD-BEARING CELL/MICROBEAD/CALCIUM PHOSPHATE BONE PASTE FOR BONE TISSUE ENGINEERING - The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same. | 02-14-2013 |
20130018232 | Method For Monitoring the Accuracy of Tissue Motion Prediction from Surrogates - A system and method for indirectly monitoring the position of a target inside a body is disclosed. The method includes generating position data associated with one or more surrogate devices and predicting a location of the target from the position data based on a target position model that establishes a relationship between an actual location of the target and the position data of the one or more surrogate devices. The method also includes determining that the predicted location of the target deviates from the actual location of the target when an analysis of an error prediction model results in a confidence threshold being exceeded. | 01-17-2013 |
20130017225 | NATURAL PLANT PRODUCTS FOR CONTROL OF CANCER METASTASIS - The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant | 01-17-2013 |
20120328692 | POTENT D-PEPTIDE ANTAGONISTS OF MDM2 AND MDMX FOR ANTICANCER THERAPY - The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists. | 12-27-2012 |
20120328526 | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof - The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD | 12-27-2012 |
20120309941 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 12-06-2012 |
20120289467 | Compositions and Methods Utilizing Fibrin Beta Chain Fragments - A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66) | 11-15-2012 |
20120282293 | Multivalent Live Vector Vaccine against Clostridium difficile-Associated Disease - The invention relates to a multivalent | 11-08-2012 |
20120251580 | METHODS OF USE FOR A NATURAL THOMSEN-FRIEDENREICH DISACCHARIDE COMPOUND - A Thomsen-Friedenreich disaccharide-containing glycopeptide purified from cod fish of approximately 100 kDa (designated TFD | 10-04-2012 |
20120208767 | Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1 - A method includes obtaining a biological sample from a subject that does not display a symptom of Painful Bladder Syndrome (PBS). The method also includes analyzing the biological sample for a mutated form of NAD(P)H dehydrogenase [quinone], also known as Quinone Oxidoreductase 1, abbreviated NQO1, or a mutation of a NQO1 gene. The method also includes determining a risk of PBS for the subject based on analyzing the biological sample. In some methods, the mutation determined to present an increased risk is a cytosine to thymine nucleotide substitution at a position that leads to a proline to serine amino acid substitution at amino acid position 187 to produce a protein NQO1P187S. Another method includes selecting a subject that has above normal risk of Painful Bladder Syndrome (PBS) or is expressing a symptom of PBS, and treating the subject with a therapeutically effective amount of an antioxidant. | 08-16-2012 |
20120195886 | SODIUM PUMP ANTIBODY AGONISTS AND METHODS OF TREATING HEART DISEASE USING THE SAME - Antibodies that are agonists of sodium pump (Na | 08-02-2012 |
20120190708 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS - The emergence of multidrug-resistant pathogens necessitates the search for new antibiotics acting on previously unexplored targets. Nicotinate mononucleotide adenylyltransferase of the NadD family, an essential enzyme of NAD biosynthesis in most bacteria, was selected as a target for structure-based inhibitor development. To this end, the inventors have identified small molecule compounds that inhibit bacterial target enzymes by interacting with a novel inhibitory binding site on the enzyme while having no effect on functionally equivalent human enzymes. | 07-26-2012 |
20120156770 | HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 06-21-2012 |
20120156187 | METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER - Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist. | 06-21-2012 |
20120109124 | ELECTROSURGICAL ELEMENT AND UTERINE MANIPULATOR FOR TOTAL LAPAROSCOPIC HYSTERECTOMY - A vaginal cervical retractor used to maneuver and visualize the uterus during various medical examinations and procedures would include an inner tube provided with a movable assembly of plastic cups (cervical cup and vaginal cup) designed to be inserted into the uterine cavity and a retractable electrosurgical needle. A cervical cup is molded to a hollow outer shaft to form the movable cup assembly. This hollow shaft is provided through which the inner tube can be inserted. By utilizing a vaginal cervical retractor elevator provided with an inner rigid tubing, freely sliding vaginal cup and cervical cup designed to move on the inner tubing, attached to a hollow, plastic outer shaft into which the inner tubing can be inserted, and a retractable, flexible, electrosurgical needle, the colpotomy procedure can be performed with the improved uterine manipulator. | 05-03-2012 |
20120107329 | EGFR and PAR2 Regulation of Intestinal Permeability - The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR | 05-03-2012 |
20120078206 | SNAP-ON TWO-PIECE EMERGENCE PROFILE HEALING ABUTMENT - The present invention relates to an apparatus for the removal and containment of human waste products from the effected area of incontinent patients. The apparatus and process encapsulates the areas of the body where urine and fecal matter are excreted. In particular, the present invention is directed to an apparatus for the containment and removal of human waste products, comprising: a receptacle; a vacuum connection to apply force for attaching the receptacle to the patient; and a vacuum dispersion membrane to provide mechanical support to the skin so as to minimize tensile force applied to the skin. | 03-29-2012 |
20120076861 | MATERIALS AND METHODS FOR THE TREATMENT OF CELIAC DISEASE - The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease. | 03-29-2012 |
20120076722 | METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION - The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of B lymphocytes and (2) anti-4-1BB (anti-CD137) antibody for inhibiting proliferation and activation and inducing death of B lymphocytes. | 03-29-2012 |
20120064105 | Engineered Type IV Pilin of Clostridium difficile - The present invention relates to engineered | 03-15-2012 |
20120064074 | ANTIGEN BINDING DOMAINS - A process for the production of an antigen specific antigen binding domain using a transformed host containing an expressible DNA sequence encoding the antigen specific antigen binding domain, wherein the antigen specific antigen binding domain is derived from a variable region of the immunoglobulin isotype NAR found in fish. | 03-15-2012 |
20120046363 | DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF HEART FAILURE - There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids (PUFAs) and doses thereof are useful for treating heart failure. In other particular aspects, the invention is drawn to the discovery that certain PUFAs and doses thereof are useful for preserving mitochondrial function in a heart failure subject. | 02-23-2012 |
20120046324 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE - The present invention relates to compounds of Formula I below and their tautomers or pharmaceutically acceptable salts, compositions and methods of uses thereof. | 02-23-2012 |
20120034620 | COMPOSITIONS AND METHODS FOR ADHESION OF INTACT CELLS TO AN APPARATUS - Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto. | 02-09-2012 |
20120029173 | ATTENUATED SALMONELLA ENTERICA SEROVAR PARATYPHI A AND USES THEREOF - The present invention is drawn to a live, attenuated | 02-02-2012 |
20120022052 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE - The present invention relates to compounds of formula Ia or Ib below and their tautomers and/or pharmaceutically acceptable salts and compositions and methods of uses thereof. | 01-26-2012 |
20120010531 | Small-Animal Unit for Muscle Injury, Muscle Testing and Muscle Training in Vivo - The invention provides a system for measuring contractile torque of skeletal muscles, performing muscle training programs, and inducing contraction-induced injury. The system is versatile and precise to measure contractile torque, train muscles, and perform contraction-induced injury protocols on living rodents. The system also allows for repeated studies of the same animal over time, thus resembling longitudinal human studies, minimizing the effect of animal-to-animal variability, and reducing the total number of animals that need to be studied. | 01-12-2012 |
20120009242 | BLOOD COAGULATION INDUCING POLYMER HYDROGEL - The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated. | 01-12-2012 |
20120004518 | TECHNIQUES FOR COMPENSATING MOVEMENT OF A TREATMENT TARGET IN A PATIENT - One embodiment includes a method of predicting a position of a target site inside a body using surrogates is provided. The method includes transforming surrogate measurements and target positions into different representations by applying an operator, establishing a special relationship between the transformed surrogate measurements and the transformed target positions, and continuously predicting the target position from the transformed surrogate measurements and the established special relationship. | 01-05-2012 |
20110311118 | Techniques for 3-D Elastic Spatial Registration of Multiple Modes of Measuring a Body - Techniques for registration of multiple measurement modes of a body include receiving first and second data from different modes. Each includes measured values with coordinate values. For two mechanically aligned modes, any non-rigid registration is performed. For some modes, the non-rigid registration includes a coarse transformation and multiple fine scale transformations. The coarse transformation maximizes a coarse similarity measure. The second data is sub-divided into contiguous sub-regions. Fine transformations are determined between the sub-regions and corresponding portions of the first data to maximize a fine similarity measure. Sub-dividing and determining fine transformations repeats until stop conditions are satisfied. Transformations between the last-divided sub-regions are interpolated. Any of the fine similarity measure, a search region, interpolation method, sub-division location, and the use of rigid or non-rigid fine transformations are adaptive to properties of the first or second data so that the registration is automatic without human intervention. | 12-22-2011 |
20110293161 | Techniques for Tomographic Image by Background Subtraction - Techniques for background subtraction in computed tomography include determining voxels in a slice of interest in a three dimensional computed tomography scan of the interior of a body based on a first set of measurements of radiation transmitted through the body. Based on the first set of measurements, a first background image for radiation transmitted through the body in a first direction is determined without the effects of the voxels in the slice of interest. A current image is determined based on a different current measurement of radiation transmitted through the body in the first direction. A first difference is determined between the current image and the first background image. The result is a high contrast image in the slice of interest even from a single current projection image. | 12-01-2011 |
20110274714 | Broad Spectrum Vaccine Against Non-Typhoidal Salmonella - The present invention is drawn to attenuated | 11-10-2011 |
20110223615 | Rapid Expression Cloning of Human Monoclonal Antibodies from Memory B Cells - The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus). | 09-15-2011 |
20110218239 | Use of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antiviral Agent - The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise an antimicrobial therapeutic agent for the treatment of viral infections of DNA and RNA viruses in humans and non-human animals. The invention is especially suitable for use in a process of treating and preventing infection by, for example, rhinoviruses, enteroviruses, and influenza viruses. | 09-08-2011 |
20110217241 | CONJUGATES OF 19F MR IMAGING TRACERS FOR USE IN MULTI-CHROMIC MRI IMAGING - Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a | 09-08-2011 |
20110193882 | TECHNIQUES FOR 3-D ELASTIC SPATIAL REGISTRATION OF MULTIPLE MODES OF MEASURING A BODY - Techniques for registration of multiple measurement modes of a body include receiving first and second data from different modes. Each includes measured values with coordinate values. For two mechanically aligned modes, any non-rigid registration is performed. For some modes, the non-rigid registration includes a coarse transformation and multiple fine scale transformations. The coarse transformation maximizes a coarse similarity measure. The second data is sub-divided into contiguous sub-regions. Fine transformations are determined between the sub-regions and corresponding portions of the first data to maximize a fine similarity measure. Sub-dividing and determining fine transformations repeats until stop conditions are satisfied. Transformations between the last-divided sub-regions are interpolated. Any of the fine similarity measure, a search region, interpolation method, subdivision location, and the use of rigid or non-rigid fine transformations are adaptive to properties of the first or second data so that the registration is automatic without human intervention. | 08-11-2011 |
20110184225 | STEP TRAINER FOR ENHANCED PERFORMANCE USING RHYTHMIC CUES - A person's step length and rate may be measured, for example, through sensors that collect spatial and temporal gait parameter data. The measurements are then used to determine the rate of a rhythmic auditory cue to improve the person's gait. For example, a system links sensors to detect step rate and length to an audio cue provided to headphones, while providing the appropriate algorithms to accomplish real time adjustments to the audio cues as needed to better help change the person's step length vs. step rate ratio in a desired direction depending on therapeutic or performance goals. | 07-28-2011 |
20110183923 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 07-28-2011 |
20110179361 | PREDETERMINED PRESENTATION OF PATIENT DATA AT BEDSID - Techniques for presenting patient data at the patient's bedside include receiving predetermined presentation style data that indicates a subset of fewer than all parameters available from an electronic medical records (EMR) system and a first arrangement on a display device of related parameters in the subset. Without human intervention, the most recent values from the EMR system are received. The most recent values are associated in the EMR system with the particular patient for corresponding parameters of the subset. A first most recent value is presented according to the first arrangement at the particular bedside display device without human intervention. In some embodiments, the most recent values are also received or presented in response to a single stroke from a human user at an input for the particular display device. | 07-21-2011 |
20110177111 | PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS - Vaccine formulations effective against | 07-21-2011 |
20110171123 | In Vivo Biofilm Infection Diagnosis and Treatment - The present invention relates to a method for in vivo detection of a biofilm infection residing in a mammal, the method comprising (i) administering to the mammal a diagnostic-effective amount of a biofilm-specific probe, wherein the probe comprises a bio film-targeting moiety and a paramagnetic nanoparticle core; and (ii) imaging the mammal to detect the presence of the biofilm infection by observing the mammal using a magnetic resonance diagnostic technique after the biofilm-specific probe has been provided sufficient time to selectively bind to the bio film infection that may be present in the mammal. The invention also relates to methods of treatment of a bio film infection, and compositions and kits useful in the detection and/or treatment of bio film infections. | 07-14-2011 |
20110144093 | METHOD OF TREATING ORGANOPHOSPHOROUS POISONING - A method for treating organophosphorous poisoning (OP) comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine. | 06-16-2011 |
20110118219 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY - Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles(azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of the steroid. Suitable prodrug groups include amino acid groups, succinate groups, phosphate groups, or sulfamate groups. The prodrugs of the disclosed compounds allow for improved oral bioavailability of the compounds that are inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds and the corresponding prodrugs are useful for the treatment of conditions such as human prostate cancer, breast cancer, and prostate hyperplasia. | 05-19-2011 |
20110105445 | ANDROGEN RECEPTOR INACTIVATION CONTRIBUTES TO ANTITUMOR EFFICACY OF CYP17 INHIBITORS IN PROSTATE CANCER - Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (AR) protein expression and methods of antagonizing AR in a mammal that include administering to the mammal an effective amount of at least one active ingredient selected from VN/124-1, VN/125-1, VN/85-1, VN/87-1 and VN/108-1. Also provided are methods of treating prostate cancer and methods of suppressing or preventing prostate tumor growth by administering such compounds to a mammal. | 05-05-2011 |
20110098935 | TECHNIQUES FOR DETERMINING THE EFFECTS ON A SYSTEM OF A COMPONENT THAT HAS FOUR STATES - Techniques for determining effects on a biological system include determining rate constants for a particular time interval starting at an initial time. Each rate constant indicates a rate of transition from one of four states to a different one of the four states for a component of a biological system in presence of an external factor. A temporal change in a probability that the component is in a particular state after the initial time is determined without numerical iteration over multiple time steps. This includes determining three relaxation time constants that describe exponential changes based on the rate constants. The effect of the external factor on the biological system is determined based on the temporal change in the probability that the component is in the particular state. The probability at an arbitrary time is determined based on the rate constants and initial probabilities. | 04-28-2011 |
20110086059 | NON-HEMOLYTIC CLYA FOR EXCRETION OF PROTEINS - The disclosure below provides a protein export system utilizing non-hemolytic variants of HlyE family member proteins for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced. | 04-14-2011 |
20110070252 | MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER - The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention. | 03-24-2011 |
20110059974 | NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS - Retinoic acid metabolism blocking agents (RAMBAs). The RAMBAs may be used for treatment of cancer, including breast and prostate cancers. Methods for preparing novel retinamide RAMBAs. The methods include reacting RAMBAs with terminal polar carboxylic acid group with a variety of amines in the presence of suitable coupling reagents. The retinamide RAMBAs are potent inhibitors of the growth of prostate and breast cancer cells and may be useful for the treatment of these diseases in humans. | 03-10-2011 |
20110052033 | COMPOSITE IMAGES FOR MEDICAL PROCEDURES - Medical imaging often involves the collective use of information presented in multiple images of an individual, such as images generated through different imaging modalities (X-ray, CT, PET, etc.) The use of a composite of these images may involve image registration to adjust for the variable position and orientation discrepancies of the individual during imaging. However, registration may be complicated by soft tissue deformation between images, and implementations (particularly pure software implementations) of the mathematical models used in image registration may be computationally complex and may require up to several hours. Hardware architectures are presented that apply the mathematical techniques in an accelerated manner, thereby providing near-realtime image registration that may be of particular use for the short timeframe requirements of surgical environments. The composite image generated thereby may be used to target anatomic features of interest during various medical procedures, including surgical procedures. Moreover, such techniques may be applied to computationally difficult image processing techniques, such as the display of a composite image based at least in part on a PET image, which may otherwise be difficult to utilize in a time-sensitive manner such as a surgical setting. | 03-03-2011 |
20110045554 | HETEROLOGOUS EXPRESSION OF EXTREMOPHILE HEAT SHOCK PROTEINS AND CHAPERONES IN MICROORGANISMS TO INCREASE TOLERANCE TO TOXIC COMPOUNDS - The invention provides methods and compositions for increasing tolerance of microorganisms to toxic agents, such as solvents; and for increasing production of solvents from solvent-generating microorganisms. The methods comprise engineering a microorganism of interest to express a heterologous heat-shock protein/chaperone, e.g., Group II chaperonin or a prefoldin such as γ-prefoldin, where the heterologous protein is from an extremophile, such as an archaean. | 02-24-2011 |
20110021440 | APOPTOTIC PATHWAY TARGETING FOR THE DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to methods of treating cancer. The invention further relates to a method of treating cancer by exploiting apoptotic pathways. The invention particularly relates to regulation of apoptotic pathways in cancerous cells, to metastasis of cancer cells, and to methods of preventing cancer metastasis. | 01-27-2011 |
20110020399 | Vaccines and Immunomodulatory Therapies for Tularemia - The present invention relates to attenuated strains of | 01-27-2011 |
20110004189 | SYSTEM AND METHOD FOR PROVIDING OPTIMAL CONCENTRATIONS FOR MEDICATION INFUSIONS - Techniques for medical infusions include determining a first infusion rate for administering a first medication to a patient. A fluid load is determined based at least in part on the first infusion rate. It is determined whether the fluid load exceeds a predetermined threshold based on a fluid maintenance rate. If it is determined that the fluid load exceeds the predetermined threshold, then an action is caused to inhibit administering the first medication to the patient at the first infusion rate. | 01-06-2011 |
20100291069 | METHODS OF TREATING A DIABETIC EMBRYOPATHY - Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy. | 11-18-2010 |
20100285496 | Methods and Devices for the Detection of Biofilm - The present invention provides methods and kits for biofilm detection. | 11-11-2010 |
20100268154 | APPARATUS AND METHOD FOR AUTOMATING AN ENEMA WITH CONTROLLED DISTENSION - An apparatus and method are provided for use in administering a rectal contrast enema to a patient to prepare the patient for a medical procedure. A rectal catheter may be provided to facilitate administration of the enema preparation to the patient. The rectal catheter may include a retention balloon. A delivery mechanism may be provided to urge the enema preparation into the patient. A vacuum may be provided to remove waste from the patient. A gas insufflator may be provided to insufflate the patient's colon for a medical procedure such as a scan, and more specifically, a virtual colonoscopy. | 10-21-2010 |
20100262203 | DETERMINATION OF SITE OF ORIGIN FOR A NATURAL ELECTRICAL PULSE IN A LIVING BODY - Techniques include determining a first vector of temporal changes in electrical data measured at multiple electrical sensors positioned at corresponding locations on a surface of a living body due to a natural electrical pulse. A different vector of temporal changes in electrical data measured at the same electrical sensors is determined due to each stimulated signal of multiple stimulated signals within the living body. Stimulated position data is received, which indicates a different corresponding position within the living body where each of the stimulated signals originates. The site of origin of the natural electrical pulse is determined based on the first vector and the multiple different vectors and the stimulated position data. Among other applications, these techniques allow the rapid, automatic determination of the site of origin of ventricular tachycardia arrhythmia (VT). | 10-14-2010 |
20100239633 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 09-23-2010 |
20100204751 | Methods for Treating Central Pain Syndrome and Other Pain Related Pathologies - Central pain syndrome (CPS) is a debilitating condition that affects a large number of patients with a primary lesion or dysfunction in the central nervous system. Despite its discovery over a century ago, the pathophysiology underlying the development and maintenance of CPS is poorly understood. The present invention is drawn to novel methods of treating CPS. In certain aspects, the invention is drawn to the novel discovery of the role of the zona incerta (ZI) in CPS and methods of exploiting this novel discovery for the treatment of CPS. | 08-12-2010 |
20100203047 | Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal - The present invention relates to compositions comprising an agent which activates herpes virus entry mediator (HVEM). The present invention also relates to compositions comprising an agonist of HVEM. The present invention also relates to methods of stimulating erythropoiesis in a mammal, comprising administering to a mammal a composition comprising an agent which activates HVEM, or is an agonist of HVEM. The present invention also relates to methods for treating an anemic disorder, comprising administering to a mammal suffering therefrom an agent which activates HVEM. | 08-12-2010 |
20100184812 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER - Mutual prodrugs comprising retinoids and histone deacetylase inhibitors, methods for production of the mutual prodrugs, and methods of treatment comprising administration of the mutual prodrugs. The retinoids include all-trans retinoic acid, 13-cis retinoic acid, and retinoic acid analogs that have a substitution at C-4. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer and dermatological diseases and conditions. Pharmaceutical compositions comprising the mutual prodrugs. | 07-22-2010 |
20100183740 | Potent Inhibitory Effect of Zinc in Combination with Sulforaphane on Cancer Cell Growth - This invention relates to compositions comprising zinc and sulforaphane which can be used in the treatment or prevention of cancer. The invention also relates to methods of treating or preventing cancer, including prostate cancer, which comprises the administration of zinc and sulforaphane to a patient in need thereof. | 07-22-2010 |
20100183646 | MAGE-A3/HPV 16 PEPTIDE VACCINES FOR HEAD AND NECK CANCER - The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention. | 07-22-2010 |
20100173323 | GLYCOSYLATION ENGINEERED ANTIBODY THERAPY - The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody. | 07-08-2010 |
20100173301 | PROGNOSTIC TOOLS TO PREDICT THE EFFICACY OF DRUG TREATMENT TARGETING CHROMATIN DNA OR ENZYMES ACTING ON DNA - Disclosed are methods of predicting cell response to drug-based therapy using both PCR-Stop assays and real time PCR assays. Methods herein may be used for assessment of drug effect, evaluation of regimen suitability for a given patient, and/or for determination of an optimal drug dose. Also provided are isolated oligonucleotide primers such as primers capable of annealing under PCR conditions to a segment of a c-myc locus, where the primers may be used in the disclosed methods. Further disclosed are kits and systems that may be used for predicting a cell response to drug-based therapy. | 07-08-2010 |
20100167392 | FACTOR VIII COMPOSITIONS AND METHODS - The present invention provides methods of increasing the half-life and/or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and/or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention. | 07-01-2010 |
20100113600 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND - A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer. | 05-06-2010 |
20100094119 | METHOD AND EQUIPMENT FOR IMAGE-GUIDED STEREOTACTIC RADIOSURGERY OF BREAST CANCER - A method of treating a cancerous region in a breast of a patient comprising (i) imaging the breast in a three-dimensional coordinate system, (ii) stereotactically determining the location of the cancerous region in the breast, (iii) optionally determining the volume of the entire cancerous region to be treated, and (iv) while maintaining the breast in a three-dimensional coordinate system that is identical to or corresponds with the three-dimensional coordinate system used in (i), noninvasively exposing the cancerous region of the breast of the patient to a cancer-treatment effective dose of radiation; and equipment for use in such a method. | 04-15-2010 |
20100081661 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY - Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase. | 04-01-2010 |
20100068802 | NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 03-18-2010 |
20100021900 | USE OF OMENTIN 1 AND OMENTIN 2 IN THE DIAGNOSIS AND TREATMENT OF DISEASE - The present invention is directed to methods of diagnosing a disease or predicting an increased risk of a disease, such as obesity, obesity-dependent subacute inflammation, atherosclerosis, cardiovascular disease and a metabolic disease, by determining the levels of omentin 1 and 2 protein in a subject, or by determining the levels of omentin 1 and 2 gene expression in a subject. The present invention is also directed to methods of disease treatment using omentin 1 protein and omentin 2 protein. | 01-28-2010 |
20090317393 | METHOD OF MODIFYING GLUCOSE ACTIVITY USING POLYPEPTIDES SELECTIVELY EXPRESSED IN FAT TISSUE - Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition. | 12-24-2009 |
20090311214 | COMPOSITIONS AND METHODS FOR THE INNATE IMMUNE RESPONSE PATHWAY - Autoimmune diseases are the consequence of complex interactions between a mosaic of host genetic factors and etiologic elements. Celiac disease (CD) is an autoimmune disease prevalent in 1% of the general population, but is unique on two accounts; a) the majority (90%) of individuals with CD have the HLA class II DQ2 allele, the others HLA-DQ8 and b) the etiologic agent is gluten proteins from wheat and related prolamins in barley and rye. The disease process is generally considered to be mediated by T cells that recognize HLA-DQ2 specific peptide sequences in gluten. There is currently no therapeutic treatment for CD. To this end, the inventors have identified a novel therapeutic target for CD and innate immune pathways in other inflammatory conditions. | 12-17-2009 |
20090161938 | QUANTITATIVE REAL-TIME 4D STRESS TEST ANALYSIS - Stress test analysis is facilitated through the acquired and manipulated use of a sequence of volumetric data regarding the heart (and may particularly comprise the left ventricle) for the assessment of the health state of the heart. Several provided and illustrated examples specifically relate to ultrasound volumetric data, but the volumetric data may be obtained through the use of any imaging modality (e.g., CT, MRI, X-ray, PET, SPECT, etc.) or combination thereof, and may be used to compute one or more functional quantitative metrics (e.g., ejection fraction.) The volumetric data may also be used to render one or more views of the heart, and particularly of the left ventricle. This disclosure relates to these and other uses of such volumetric data, and to some various implementations thereof, such as methods, systems, and graphical user interfaces. | 06-25-2009 |
20090143450 | METHOD FOR TREATING CENTRAL PAIN SYNDROM OR FOR INDUCING CENTRALLY GENERATED PAIN IN AN ANIMAL MODEL - The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels. | 06-04-2009 |
20090130144 | Direct vaccination of the bone marrow - The present invention provides methods for eliciting an effective immune response against a weakly immunogenic disease or for priming T cells to become memory T cells against a weakly immunogenic disease by directly vaccinating into the bone marrow of the patient an antigen associated with the weakly immunogenic disease. Also included in the present invention is an isolated population of human memory CD8 | 05-21-2009 |
20090124570 | Methods and Compositions for Facilitating Tissue Repair and Diagnosing, Preventing, and Treating Fibrosis - Compositions and methods for facilitating tissue repair by enhancing the actions of BIGH3 or at least one of its downstream effector molecules in injured tissue, and for the diagnosis, prophylactic and therapeutic treatment of fibrosis by inhibiting the actions of BIGH3 or at least one of its downstream effector molecules, such as PU.1 transcription factor and MMP14. Other disclosed methods include methods of screening and/or identifying compounds useful for facilitating tissue repair, treating fibrosis, or for altering the accumulation or deposition of collagen, comprising contacting BIGH3 or its downstream effector molecules, such as PU.1 or MMP14, with a substance and subsequently determining the effects of the substance on the activity of BIGH3, PU.1, or MMP14. | 05-14-2009 |
20090111120 | METHYLATION OF GENES AS A PREDICTOR OF POLYP FORMATION AND RECURRENCE - The present invention provides methods for identifying or assessing probabilities for developing an abnormal condition in subject and for the recurrence of the abnormal condition in the subject after receiving treatment. The method comprises determining the methylation status of at least one gene in the subject and comparing this methylation status to normal methylation status. Differences between the methylation status of the one or more genes is indicative of the subject developing an abnormal condition or for the recurrence of the abnormal conditions after receiving treatment. | 04-30-2009 |
20090104199 | Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It - The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs. | 04-23-2009 |
20090082279 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 03-26-2009 |
20090048153 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME - One embodiment of the present invention provides a composition, comprising, in amounts effective to treat sulfur mustard or half sulfur mustard induced toxicity or skin damage: an agent that inhibits alkylation of —SH and >NH protein groups; an agent that reduces —SS— to SH; a scavenger of reactive oxygen species; a substrate that maintains tissue reduction-oxidation status; an agent that protects against invading inflammatory cells and associated oxidative stress; an antagonist of prostaglandin synthesis; and an agent that induces tissue regeneration. Methods of using the composition are also provided. | 02-19-2009 |
20090047703 | ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease - The present invention relates to peptide and polynucleotide fragments of ERG-1, and in particular, human ERG-1a (HERG-1a) and its isoforms, and their use in the treatment and diagnosis of disease, especially cardiac diseases, such as arrhythmias, and cancer. | 02-19-2009 |
20090023706 | Method of Treating Organophosphorous Poisoning - The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus poisoning in an animal that has been exposed to an organophosphorus compound, by administering a therapeutically effective amount of galantamine or a salt thereof, or a biologically active analog, derivative, fragment or variant thereof. | 01-22-2009 |
20090010923 | TREATMENT OF CANCER WITH ANTI-MUSCARINIC RECEPTOR AGENTS - The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor. | 01-08-2009 |
20080286310 | Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle - The invention provides live, attenuated enterohemorrhagic | 11-20-2008 |
20080269136 | METHOD OF USE OF PEPTIDE ANTAGONISTS OF ZONULIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 10-30-2008 |
20080260760 | Prostate-Specific Antigen-Derived Mhc Class H-Restricted Peptides and Their Use in Vaccines to Treat or Prevent Prostate Cancer - The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer. | 10-23-2008 |
20080249054 | METHOD OF MEASURING LIPID DROPLETS AND APPLICATIONS OF USING THE SAME - The invention relates to methods of screening agents for the ability to regulate lipid metabolism and using said agents to treat diseases or disorders related to lipid metabolism (e.g., obesity, diabetes [non-insulin and insulin dependent], hypertension, coronary artery disease, hyperlipidemia (e.g., LDL, TAGs), hypolipidemia (e.g., HDL), lipid metabolism disorders, lipid deposition disorders, lipodystrophies). In specific embodiments, the invention relates to using a PAT family protein to screen agents for the ability to regulate lipid metabolism and using the same to treat diseases or disorders related to lipid metabolism. In further embodiments, the invention relates to high throughput screening (HTS) methods that can be used in the drug discovery process for screening agents for the ability to regulate lipid metabolism. | 10-09-2008 |
20080233094 | Attenuated Salmonella Enterica Serovar Paratyphi a and Uses Thereof - The present invention is drawn to a live, attenuated | 09-25-2008 |
20080219972 | Prostatic Acid Phosphatase (Pap) Materials and Methods of Use Thereof in the Prophylactic and Therapeutic Treatment of Prostate Cancer - A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-cell line that produces an anti-idiotypic monoclonal antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41. | 09-11-2008 |
20080212737 | Techniques For Compensating Movement of a Treatment Target in a Patient - Techniques for improving treatment delivered to a target site in a patient include delivering a treatment from a treatment delivery device to a target site in a patient supported by a patient support structure. During the delivery of treatment, a state of the patient is measured to produce real-time measurement data. Measuring the state is non-invasive; and the measured state is a correlated surrogate for position of the target site. Compensating movement data is determined based on the real-time measurement data to cause the target site to maintain a particular spatial relationship with the treatment delivery device. Either the treatment delivery device, or the support structure, or both, are moved based on the compensating movement data. When the delivery device alone is moved, the correlation between measured state and target site is based on partial least squares applied to pre-treatment measurements of both. | 09-04-2008 |
20080199357 | Integrated centrifugal blood pump-oxygenator, an extracorporeal life support system and a method of de-bubbling and priming an extracorporeal life support system - The invention relates to an integrated centrifugal blood pump-oxygenator ( | 08-21-2008 |